Archives
-
Moxifloxacin Workflows for Translational Research
2026-09-11
Moxifloxacin supports more than routine antibacterial testing: it can connect DNA gyrase inhibition with cell viability, retinal ganglion cell proliferation, and systemic metabolic responses. This practical guide covers preparation, assay design, comparative mechanistic experiments, and troubleshooting for reproducible antibiotic toxicity research.
-
Ciprofloxacin: Research Workflows and Optimization
2026-09-10
Build more reproducible antibacterial, resistance, and nanotheranostic assays with Ciprofloxacin, from solvent and dilution planning to matched controls for ultrasound-enabled delivery. The workflow also translates a recent ZIF8-based tumor study into practical assay decisions without overstating the compound’s cross-domain evidence.
-
A-769662 and the New Logic of AMPK Signaling
2026-09-10
A translational perspective on A-769662 as an AMPK activator, integrating energy metabolism, autophagy, proteasome biology, and experimental strategy for metabolic disease research.
-
DAPT (GSI-IX) in Cell-Fate Assay Design
2026-09-09
DAPT (GSI-IX) is a γ-secretase probe for separating APP processing from Notch-dependent cell-state decisions. This article explains how to use it more rigorously in combination media, disease models, and pathway-focused assays.
-
Mithramycin A Workflows for Gene Regulation
2026-09-09
Mithramycin A is an anticancer antibiotic that enables mechanistic studies of G-C-rich transcriptional control, c-myc regulation, and myeloid differentiation. This workflow-focused guide connects leukemia assays with carefully bounded applications in doxorubicin injury models while emphasizing controls, dose-finding, and troubleshooting.
-
Mithramycin A: DNA-Targeted Assay Workflows
2026-09-08
Mithramycin A turns metal-dependent recognition of G-C-rich DNA into a practical perturbation tool for transcription, c-myc regulation, and myeloid differentiation. This workflow-focused guide also shows how to evaluate its hypothesis-generating use alongside the miR-24-3p/Sp1/PI3K findings in cardiac injury research without mistaking a broad transcriptional probe for a pathway-specific inhibitor.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis
2026-09-08
A recent Free Radical Biology and Medicine study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating epoxyeicosatrienoic acid metabolites and suppresses Nrf2–ARE signaling during osteoporosis. Clinical samples, ovariectomized mice, liver-specific knockdown, pharmacological inhibition, and osteoclast cultures collectively connect redox imbalance with osteoclast differentiation, while also defining important limits for translation to other research settings.
-
Drug Response Metrics for Cancer In Vitro Studies
2026-09-07
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for separating growth inhibition from cell killing while considering their different proportions and temporal behavior, with direct implications for evaluating DNA methyltransferase inhibitors and other cancer therapies.
-
S Tag Peptide: Practical Fusion-Tag Workflow
2026-09-07
S Tag Peptide provides a compact, charged 15-amino-acid sequence for recombinant protein detection and protein solubility improvement when genetically fused to a target protein. This guide covers handling, construct design, QC, and troubleshooting, while clarifying that the free peptide is not a substitute for a validated recombinant fusion construct or antibody-based capture system.
-
Niclosamide Workflows for STAT3 Cancer Research
2026-09-05
Niclosamide enables a practical, multi-readout strategy for studying STAT3 Tyr-705 phosphorylation, proliferation, apoptosis, and NF-κB signaling in cancer models. This guide combines product-specific handling with disciplined concentration–response design and assay lessons adapted cautiously from a recent molluscicide study.
-
CFDA SE Cell Tracer Kit: Practical Guide
2026-09-04
The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for multi-day cell tracking, cell proliferation studies, and cell lineage tracing. It is appropriate for covalent live-cell marking but should not be selected for reversible labels, real-time physiological monitoring, or experiments that require an unvalidated universal staining concentration.
-
Saquinavir: From Protease Target to Assay Design
2026-09-04
Saquinavir is a valuable HIV protease inhibitor for linking antiviral mechanism with membrane-aware assay design. This article translates comparative IAM-LC and LEKC findings into practical decisions for antiretroviral drug research, HIV infection research, and translational workflows.
-
BKT140 (BL-8040) CXCR4 Assay Workflows
2026-09-03
Build more informative CXCR4 experiments with BKT140, from chemotaxis and apoptosis readouts to hematopoietic stem cell mobilization. This workflow-focused guide connects functional antagonist assays with receptor-aware oncology models and emerging CXCR4 theranostic strategies.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-03
The reference study identifies an LMO2/LDB1 protein complex as a functional regulator of acute myeloid leukemia cell proliferation and survival. By integrating gene perturbation, protein-interaction mapping, transcriptomics, chromatin profiling, and rescue experiments, it connects LDB1-dependent transcriptional control with apoptosis-related programs and highlights a potential leukemia-maintenance vulnerability.
-
AM251 Workflows for CB1 Receptor Research
2026-09-02
AM251 is a nanomolar CB1 receptor antagonist for separating CB1-dependent signaling from broader endocannabinoid effects. This practical guide translates pain-model findings into reproducible workflows for neuroscience research, metabolic studies, receptor pharmacology, and apoptosis assays.